文献速递头颈外科咽喉与嗓音

T3N0M0声门型喉鳞癌的生存结局

Survival Outcomes for Patients With T3N0M0 Squamous Cell Carcinoma of the Glottic Larynx.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2017-01-01

基于美国国家癌症数据库2004至2013年数据,回顾性分析2622例接受根治性治疗的临床T3N0M0声门型喉鳞癌患者。初治手术与初治放疗的5年总生存率无统计学差异,支持以放疗为基础保喉方案在不牺牲总生存的前提下用于该类患者。

要点

  • T3N0M0声门型喉鳞癌初治手术与初治放疗的5年OS无统计学差异
  • 调整后总体5年生存概率为53%
  • 年龄增长、保险状态与合并症增多与总生存下降相关

核心结论

  • 现行T3N0M0声门型喉癌治疗主要依赖以放疗为基础的保喉方案。
  • 本研究支持以放疗为基础的保喉方案用于T3N0M0声门型喉癌且不损害总生存。

研究设计与样本

  • 回顾性队列研究,数据来自美国国家癌症数据库。
  • 纳入2004年1月1日至2013年12月31日治疗的患者,中位随访58个月(范围0-126.6个月)。
  • 4003例T3N0M0患者中2622例接受研究方案定义的根治性治疗并纳入分析。

主要发现

  • 分析队列共2622例,男2251例(85.9%)、女371例(14.1%),中位年龄64岁(范围19-90岁)。
  • 总体队列调整后5年生存概率为53%。
  • 初治手术组5年生存53%(95%CI,48%-57%),初治放疗组54%(95%CI,52%-57%),两组无统计学差异。
  • 多因素分析中与OS下降相关的因素:年龄(HR,1.04;95%CI,1.03-1.04)、保险状态(HR,1.26;95%CI,1.06-1.50)、合并症增多(HR,1.20;95%CI,1.02-1.42)。

临床怎么用

  • 对T3N0M0声门型喉鳞癌,可在充分评估后选择以放疗为基础的保喉方案,总生存与初治手术相当。
  • 决策时需综合年龄、保险状态与合并症等影响总生存的患者因素。

局限性

  • 为回顾性队列研究,数据来源于登记数据库。
  • 研究方案对根治性治疗有界定,4003例中仅2622例纳入分析,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Radiotherapy (RT)-based organ preservation approaches for patients with advanced laryngeal cancer have been established stepwise through prospective randomized clinical trials. However, broad adoption of these approaches has stimulated discussion about long-term results challenging their applicability in a heterogeneous patient population, most recently for patients with T3 disease. OBJECTIVE: To define outcomes in patients with clinical T3N0M0 glottic laryngeal cancer treated with definitive surgical and RT-based approaches. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included patients treated from January 1, 2004, through December 31, 2013, with a median follow-up time of 58 months (range, 0-126.6 months) in the National Cancer Database. Of the 4003 patients with T3N0M0 disease, 2622 received definitive therapy defined by the study protocol. Data were obtained from the clinical oncology database sourced from hospital registry data that are collected from more than 1500 Commission on Cancer-accredited facilities. Data were analyzed from September 14, 2016, through April 24, 2017. INTERVENTIONS: Radiotherapy, chemoradiotherapy, surgery, surgery and RT, or surgery and chemoradiotherapy. MAIN OUTCOMES AND MEASURES: Five-year overall survival (OS). RESULTS: A total of 2622 patients (2251 men [85.9%] and 371 women [14.1%]; median age, 64 years [range, 19-90 years]) were included in the analytic cohort. In the overall patient cohort, the adjusted 5-year survival probability was 53%. No statistical differences were observed between the primary surgery (53%; 95% CI, 48%-57%) and primary RT (54%; 95% CI, 52%-57%) cohorts. In multivariate analysis, patient factors associated with decreased OS included age (hazard ratio [HR], 1.04; 95% CI, 1.03-1.04), insurance status (HR, 1.26; 95% CI, 1.06-1.50), and increasing comorbidity (HR, 1.20; 95% CI, 1.02-1.42). CONCLUSIONS AND RELEVANCE: Current management of T3N0M0 glottic laryngeal cancer relies largely on RT-based organ preservation approaches. The present study substantiates randomized clinical trial data supporting the use of RT-based organ preservation approaches for patients with T3N0M0 glottic laryngeal cancer without compromising OS.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Ko HC, Harari PM, Chen S, et al. Survival Outcomes for Patients With T3N0M0 Squamous Cell Carcinoma of the Glottic Larynx. JAMA Otolaryngol Head Neck Surg. 2017. PMID: 29049434. doi:10.1001/jamaoto.2017.1756

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。